CAYMAN ISLAND – Health institution makes history, introduces new device to treat heart failure

For the first time in the Caribbean, Central and South America, a leading physician has implanted a Cardiac Contractility Modulation (CCM) device to treat heart failure.

Dr Ravi Kishore, Chief Interventional Cardiologist and Electrophysiologist at Health City Cayman Islands, implanted the device in a Cayman Islands resident in August, making medical history in the region.

“This is the first time we have introduced this device in the entire Caribbean. It’s an investigational device so it’s not routinely implanted in patients in the U.S. and none of them (has) been implanted in Central America and South America. In that sense, I think we have introduced yet another novel therapy in the region,” Dr Kishore said.

The device used for this procedure is the Optimizer IVs Active Implantable Pulse Generator (IPG) by Impulse Dynamics, which is intended for the treatment of heart failure through delivery of CCM signals.

CCM device implantation is currently conducted only on an investigational basis in the United States, however, CCM devices are approved and available for clinical use in all European Union countries as well as Australia, Turkey, India and Hong Kong. While CCM therapy is not approved for clinical use in the United States, a study has been initiated to obtain U.S. Food and Drug Administration (FDA) approval.

“We are very happy introducing a new device for our patients in the Cayman Islands…this is specifically used in patients with congestive heart failure where the heart pumping function has come down in spite of medications,” Dr Kishore said.

He explained how CCM therapy works: “The CCM device functions by giving non-contractile stimuli to the heart. It modulates the metabolism of the heart in such a way that its contractile function improves.”

In contrast to other electrical stimulation treatments for heart failure, such as pacemaker therapy and implantable cardioverter defibrillators (ICD), CCM does not affect the cardiac rhythm directly. Rather, the aim is to enhance the heart’s natural contraction sustainably over long periods of time.

“One of the traditional methods for this has been what is called cardiac resynchronization therapy (CRT) where we implant a special pacemaker, which kind of normalizes the conduction abnormality in the heart. All patients are not eligible for this, it depends on what the shape of the electrocardiogram (ECG) is like, and in some patients where the ECG does not allow a beneficial impact because of CRT we need to look at alternative options,” Dr Kishore explained.

Between 60 percent and 70 percent of patients are not eligible for traditional CRT, and are, therefore, potential candidates for CCM therapy.

Dr Kishore said: “We had one such eligible patient who had to have recurrent hospital admissions despite treatment with medication. His pumping function had come down to something like 25 percent to 30 percent, normal is 60 percent. By doing this particular device he is showing a remarkable improvement, just at two weeks after implant.”